Drug intelligence / Profile preview

orexin A

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intracerebroventricular (experimental/preclinical), Intraperitoneal (experimental/preclinical)
01

Overview

Orexin A is a **neuropeptide** also known as hypocretin-1. It is one of two forms of orexin (the other being orexin B) produced by neurons in the hypothalamus. Orexin A regulates arousal, wakefulness, appetite, and energy expenditure. It acts primarily by binding to **orexin receptors OX1 and OX2** on neurons, promoting wakefulness and maintaining stable periods of alertness. Orexin A also plays a role in regulating feeding behavior, energy homeostasis, mood (with higher levels associated with positive mood states), and lipid metabolism by increasing glucose uptake, enhancing lipogenesis, inhibiting lipolysis, and stimulating adiponectin secretion. Dysfunction or loss of orexin A signaling is implicated in sleep disorders such as narcolepsy, while exogenous administration can increase wakefulness and food intake in animal models[2][6]. Orexin A is an endogenous peptide, not a marketed pharmaceutical product, though its receptor system is being targeted in drug development.

Other names
hypocretin-1hypocretin1hypocretin 1OXA
02

Targets

HCRTR1 (Orexin/hypocretin receptor type 1)HCRTR2 (Orexin/hypocretin receptor type 2)

Beyond the preview

Go deeper on orexin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on orexin A.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call